TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including GLP-1 therapies, to older adults. It calls for assessing function, nutrition and cognition before treatment and pairing medication with measures such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has published a case-based framework to help clinicians prescribe obesity medications safely and in a patient-centered way for older adults. The paper applies the AGS Geriatrics 5Ms to incretin therapies, including GLP-1 medications, and stresses assessment of physical function, nutrition and cognition before treatment.
Published in the Journal of the American Geriatrics Society, the paper was developed by the AGS Healthy Aging Special Interest Group. It organizes its guidance around clinical cases and considers how the Geriatrics 5Ms—Mind, Mobility, Medications, Multicomplexity and Matters Most—can inform decisions about incretin therapy in older patients.
The authors point to potential benefits of obesity medications for weight management and glycemic control, while noting that older adults are underrepresented in clinical trials. They emphasize that prescribing decisions should account for age-related concerns, including frailty, sarcopenia, lean muscle loss, malnutrition and dehydration.
The framework calls for pretreatment assessment of functional status, nutritional adequacy and cognitive impairment. It also recommends pairing medication with supportive measures, including resistance training and sufficient dietary protein. Depending on a patient’s needs, care may involve a registered dietitian, physical therapist, fitness trainer or behavioral health professional.
Balancing Weight Loss With Healthy Aging
The framework addresses a clinical decision that can carry different considerations in later life than in younger adulthood. A medication’s potential effects on weight and blood sugar need to be considered alongside mobility, strength, nutritional status and a person’s broader health needs. The paper’s emphasis is on evaluating these factors before treatment rather than treating a prescription as a stand-alone intervention.
For patients and clinicians, this offers a structured way to discuss whether treatment aligns with an older person’s goals and circumstances. The suggested exercise, nutrition and team-based supports also signal that medication management may require coordination beyond the prescribing clinician. The framework is guidance, however, not evidence that every older adult will benefit from these drugs or that the proposed approach has been shown to improve outcomes.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Bowflex SelectTech 840 Adjustable Kettlebell
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
As an affiliate, we earn on qualifying purchases.
The Geriatrics 5Ms in Prescribing
The AGS 5Ms framework groups common elements of older-adult care: Mind (including cognition and mood), Mobility, Medications, Multicomplexity (the interaction of health conditions and care needs), and Matters Most (the patient’s priorities). The new paper uses those categories to organize questions clinicians can consider when discussing incretin therapy.
The source report says older adults have been underrepresented in clinical trials of obesity medications. That leaves clinicians with particular reason to consider individual health and functional factors when applying available evidence to older patients. The paper is titled “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing,” by Elias M. Wisdom and colleagues, and was published in 2026.
Evidence Gaps and Patient Differences
The source material does not provide trial results showing whether using the framework changes outcomes, nor does it establish how much benefit or risk a particular medication carries for different groups of older adults. Older adults’ underrepresentation in clinical trials is identified as a limitation, but the report does not quantify that gap or specify how well findings apply across different ages, levels of frailty or health conditions.
The framework also does not offer a single prescribing rule for all patients. The available report gives no detailed medication-by-medication recommendations, dosing guidance or thresholds for deciding when treatment should be avoided. Decisions remain dependent on individual assessment and clinical judgment; the source does not say how often each suggested co-intervention is needed or how care teams should be assembled in different settings.
Applying the Framework in Clinical Care
The paper is now available in the Journal of the American Geriatrics Society for clinicians to use as a case-based resource. Its practical next step is to bring the 5Ms into conversations about treatment: review function, nutrition and cognition, discuss the patient’s priorities, and consider supportive services alongside medication.
The source report does not announce a follow-up study, implementation program or timeline for updated guidance. Further research would be needed to clarify how obesity medications affect older adults across different health and functional profiles and whether care built around this framework improves patient outcomes. For now, the publication offers a structured approach, while leaving individual treatment decisions to patients and their clinicians.
Key Questions
What did the American Geriatrics Society publish?
The AGS published a case-based framework for clinicians prescribing obesity medications to older adults. It applies the Geriatrics 5Ms to incretin therapies, including GLP-1 medications.
What should clinicians assess before prescribing?
The framework highlights pretreatment assessment of functional status, nutritional adequacy and cognitive impairment, alongside age-related concerns such as frailty and risk of muscle loss.
What supports does the framework recommend alongside medication?
It recommends considering resistance training and adequate dietary protein. Some patients may also benefit from coordinated support involving professionals such as dietitians, physical therapists or behavioral health providers.
Does the framework establish that obesity medications are safe for every older adult?
No. It is a prescribing framework, not a guarantee of safety or benefit for every patient. The report notes that older adults are underrepresented in clinical trials and emphasizes individualized clinical assessment.
Source: medicalxpress.com
